Sichuan Kelun Pharmaceutical Co Ltd Market Cap ($9.95 Billion)
Market Cap & Net Worth: Sichuan Kelun Pharmaceutical Co Ltd (002422)
Sichuan Kelun Pharmaceutical Co Ltd market cap. Sichuan Kelun Pharmaceutical Co Ltd (SHE:002422) has a market capitalization of $9.95 Billion (CN¥68.01 Billion) as of October 27, 2026. Listed on the SHE stock exchange, this China-based company holds position #2197 globally and #219 in its home market, demonstrating a 9.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sichuan Kelun Pharmaceutical Co Ltd's stock price CN¥42.75 by its total outstanding shares 1590781208 (1.59 Billion).
Sichuan Kelun Pharmaceutical Co Ltd Market Cap History (2015–2026)
Sichuan Kelun Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $3.74 Billion to $9.95 Billion (10.68% CAGR). Check 002422 live share price for real-time trading data and today's change.
Sichuan Kelun Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sichuan Kelun Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 002422 cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.37x
Sichuan Kelun Pharmaceutical Co Ltd's market cap is 0.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.01x
Sichuan Kelun Pharmaceutical Co Ltd's market cap is 4.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.27 Billion | $8.57 Billion | $584.64 Million | 0.38x | 5.60x |
| 2017 | $5.10 Billion | $11.43 Billion | $748.54 Million | 0.45x | 6.82x |
| 2018 | $4.26 Billion | $16.35 Billion | $1.21 Billion | 0.26x | 3.51x |
| 2019 | $4.88 Billion | $17.64 Billion | $937.86 Million | 0.28x | 5.20x |
| 2020 | $4.12 Billion | $16.46 Billion | $829.39 Million | 0.25x | 4.97x |
| 2021 | $4.08 Billion | $17.28 Billion | $1.10 Billion | 0.24x | 3.70x |
| 2022 | $5.88 Billion | $19.04 Billion | $1.71 Billion | 0.31x | 3.45x |
| 2023 | $6.55 Billion | $21.45 Billion | $2.46 Billion | 0.31x | 2.67x |
| 2024 | $6.97 Billion | $21.81 Billion | $2.94 Billion | 0.32x | 2.37x |
| 2025 | $6.83 Billion | $18.51 Billion | $1.70 Billion | 0.37x | 4.01x |
Competitor Companies of 002422 by Market Capitalization
Companies near Sichuan Kelun Pharmaceutical Co Ltd in the global market cap rankings as of October 27, 2026. See 002422 equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to Sichuan Kelun Pharmaceutical Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #13 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #45 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #13 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1273.46 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $263.81 |
| #45 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $285.64 |
Market Capitalization of Sichuan Kelun Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Sichuan Kelun Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Sichuan Kelun Pharmaceutical Co Ltd's market cap moved from $3.74 Billion to $ 9.95 Billion, with a yearly change of 10.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥9.95 Billion | +45.66% |
| 2025 | CN¥6.83 Billion | -1.94% |
| 2024 | CN¥6.97 Billion | +6.44% |
| 2023 | CN¥6.55 Billion | +11.41% |
| 2022 | CN¥5.88 Billion | +43.92% |
| 2021 | CN¥4.08 Billion | -0.98% |
| 2020 | CN¥4.12 Billion | -15.53% |
| 2019 | CN¥4.88 Billion | +14.56% |
| 2018 | CN¥4.26 Billion | -16.50% |
| 2017 | CN¥5.10 Billion | +55.81% |
| 2016 | CN¥3.27 Billion | -12.50% |
| 2015 | CN¥3.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 26th, 2026 the market cap of Sichuan Kelun Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.95 Billion USD |
| MoneyControl | $9.95 Billion USD |
| MarketWatch | $9.95 Billion USD |
| marketcap.company | $9.95 Billion USD |
| Reuters | $9.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, ve… Read more